FDA opens up Bellerophon's gas therapy for COVID-19, stock rockets
Friday, March 20, 2020
Using a regulatory pathway that allows patients with life-threatening conditions to use unapproved therapies, the FDA has granted “emergency expanded access” to Bellerophon Therapeutics’ inhaled nitric oxide delivery system for treating the novel coronavirus.
No comments:
Post a Comment